furan-2-ylmethyl-(2-phenylquinazolin-4-yl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: furan-2-ylmethyl-(2-phenylquinazolin-4-yl)-amine
• 英文别名: N-[(Furan-2-Yl)methyl]-2-Phenylquinazolin-4-Amine；N-(furan-2-ylmethyl)-2-phenylquinazolin-4-amine
• 化学式: C₁₉H₁₅N₃O
• 分子量: 301.348
• InChiKey: AZNLVBWSZDPKAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-呋喃甲胺 、 4-氯-2-苯基喹唑啉 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以84%的产率得到furan-2-ylmethyl-(2-phenylquinazolin-4-yl)-amine
  参考文献：
  名称：

  Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as anti-prion agents

  摘要：

  Transmissible spongiform encephalopathies (TSEs) are thought to arise from aggregation of a protease resistant protein denoted PrPSc, which is a misfolded isoform of the normal cellular prion protein PrPC. Using virtual high-throughput screening we have selected structures analogous to acridine, 2-methyquinoline and 2-phenylquinazoline as potential therapeutic candidates for the treatment of TSEs. From the synthesis and screening of constructed libraries we have shown that an electron-rich aromatic ring attached through an amine linker to the position para to the ring nitrogen is beneficial to both binding to PrPC and the suppression of PrPSc accumulation for acridine and 2-methylquinoline analogues. 2-Phenylquinazoline analogues appear to utilise a different mode of action by binding at a different location and/or pose. We report IC(50)s in the nanomolar range. (c) 2006 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2006.05.002

文献信息

• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
• US7678802B2
  申请人：——

  公开号：US7678802B2

  公开（公告）日：2010-03-16
• US7713983B2
  申请人：——

  公开号：US7713983B2

  公开（公告）日：2010-05-11
• US8153642B2
  申请人：——

  公开号：US8153642B2

  公开（公告）日：2012-04-10
• US8343980B2
  申请人：——

  公开号：US8343980B2

  公开（公告）日：2013-01-01